Please use this identifier to cite or link to this item:
https://hdl.handle.net/20.500.12530/36400| Title: | Raltegravir plus abacavir/lamivudine in virologically suppressed HIV-1-infected patients: 48-week results of the KIRAL study. | |
| Authors: | ||
| Mesh: | ||
| Issue Date: | 2018 | |
| Citation: | PLoS ONE.2018;(13)6:e0198768 | |
| Abstract: | Long-term combination antiretroviral therapy often results in toxicity/tolerability problems, which are one of the main reasons for switching treatment. Despite the favorable profile of raltegravir (RAL), data on its combination with abacavir/lamivudine (ABC/3TC) are scarce. Based on clinical data, we evaluated this regimen as a switching strategy. | |
| PMID: | 29902204 | |
| URI: | https://hdl.handle.net/20.500.12530/36400 | |
| Rights: | openAccess | |
| Appears in Collections: | Hospitales > H. U. Infanta Leonor > Artículos Hospitales > H. U. Severo Ochoa > Artículos Fundaciones e Institutos de Investigación > IIS H. U. La Princesa > Artículos Fundaciones e Institutos de Investigación > IIS H. U. La Paz > Artículos Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos Fundaciones e Institutos de Investigación > FIB H. U. Príncipe de Asturias > Artículos | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| PMC6002106.pdf | 1.92 MB | Adobe PDF |  View/Open |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.